RxDoctor Payments Data

Jessica Schmidt, APRN

Nurse Practitioner · Hutchinson, KSNPI 1073029740

Payments from drug & device makers

$4,532in general payments, 2019–2025

Across 275 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$519
  • Amgen$342
  • Boehringer Ingelheim$312
  • AbbVie$269
  • Dexcom, Inc.$265
  • Novo Nordisk$256
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$1754%
  • Food & beverage$4,25894%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,532 in reported general payments places this provider in the 90th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$55,597
Medicare patients
384
Services billed
3,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$141,426
TrulicityDulaglutide48$45,083
MounjaroTirzepatide32$36,819
JardianceEmpagliflozin20$19,195
Novolog FlexpenInsulin Aspart19$9,880
Tresiba Flextouch U-100Insulin Degludec15$9,718
Tirosint-SolLevothyroxine Sodium14$5,040
Levothyroxine Sodium376$2,934
SynthroidLevothyroxine Sodium51$2,502
Liothyronine Sodium66$2,060
Testosterone Cypionate26$1,293
Glipizide23$1,022
Methimazole109$684
Duloxetine Hcl17$569
Hydrocortisone13$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$256$141,42693 claims
Lilly USA, LLCTrulicity, Mounjaro$198$81,90380 claims
Boehringer IngelheimJardiance$312$19,19520 claims
IBSA Pharma Inc.Tirosint-Sol$55$5,04014 claims
AbbVieSynthroid$269$2,50251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Hutchinson

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →